The remarkable anticancer effects and low toxicity of monoclonal antibodies in our preclinical models suggest that VEGFR1 and VEGFR2 antibodies could have a clinical role in treatment of ESCC. The gene discussed is KDR; the disease is esophageal squamous cell carcinoma.